Suggested remit: To appraise the clinical and cost effectiveness of canakinumab within its marketing authorisation for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein.
As you will be aware The Department for Health and Social Care has asked NICE to conduct an appraisal of canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein. However, the company have advised that they will not be pursuing a marketing authorisation application for canakinumab from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme. As this appraisal has been referred, NICE will continue to monitor the situation and update interested parties if the situation changes.
 
Status Suspended
Process STA pre-2018
ID number 1362

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
19 February 2020 Expected publication
21 January 2019 Suspended. As you will be aware The Department for Health and Social Care has asked NICE to conduct an appraisal of canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein. However, the company have advised that they will not be pursuing a marketing authorisation application for canakinumab from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme. As this appraisal has been referred, NICE will continue to monitor the situation and update interested parties if the situation changes.
03 April 2018 - 01 May 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance